opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
Medical Monitor action due to lack of compliance with audit.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Medication expired	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Medtronic acquisition of Restore Medical, business decision"	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Melagatran/ximelagatran was withdrawn from the market and clinical development in February Ê 2006 in the interest of patient safety.	[ "Safety_Sideeffects", "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	true	false	false	false
Merged with the study NCT00307268	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Met criteria for study futility at interim analysis	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Missing evidence of the effectiveness of the study medication	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Modifications will be necessary before full IRB approval will be secured.	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
Modified dose schedule presented no advantage over previously studied schedule	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Molecule Development was Terminated	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
More cases of Febrile Neutropenia were observed in experimental group compared to standard treatment.	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
More progressive stroke in one arm	[ "Endpoint_Met" ]	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false
More than 2 of 6 patients treated experienced dose limiting toxicities.	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Most patients were unable to perform the test being used to measure lung function, thus it became clear the study would not yield clinically meaningful data"	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Most pts requested to be treated with versed. It was difficult to randomize pts.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Moved study to USA	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Multiparas study terminated due to poor recruitment. Randomization revealed only after decision recorded on clinicaltrials.gov	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Music therapist left position.	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Mutual decision by site and sponsor because of difficulty recruiting Patients.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Myriad has discontinued the development of Flurizan.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
NCI not moving forward with study execution.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
NIH grant ended.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
NO available budget and difficulty in recruiting	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
NOT A CLINICAL TRIAL	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
NYU 03-67 reached accrual prior to this study opening.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Need amendments in application process and require IBD number from FDA	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Need for re-formulation	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Need funding and scientific collaborator	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Need to review design	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Needed PET facility closed	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Negative data from another trial led to termination of this trial by sponsor.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Negative efficacy results of the MAESTRO-01 study	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Negative efficacy results of the MAESTRO-01 trial	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Negative feasibility assessment of recruiting the planned number of subjects within the study timelines	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part Ê I of the study.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Negative sorafenib results from ESCAPE trial and safety concerns of regimen	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Negativity of the first results of in vivo binding of 18F-PBR06	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Negotiations in progress regarding payment for drug.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Nephrotoxicity	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Never received final IRB approval for amendments, so never opened officially"	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
New clinical finding with Celebrex and cardiac concerns.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab	[ "Safety_Sideeffects", "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
New data makes this trial unethical	[ "Ethical_Reason" ]	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false
New departmental administration, loss of key study faculty	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
New enrollment has been suspended, currently following previously enrolled participants"	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
New enrollment is temporarily suspended due to COVID19 restrictions	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New evidence and trouble recruiting	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New funding sources being sought	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New information on IMP affected the cost/benefit ratio	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New information suggested a more effective treatment protocol.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New medications with improved response released, nonaccrual	[ "Insufficient_Enrollment", "Another_Study" ]	true	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
New research priorities	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New studies are being offered	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New study planned.	[ "Business_Administrative", "Another_Study" ]	true	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New study with lenalidomide pending	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
New study written	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Newer technologies available; poor accrual to study.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Newly identified safety concerns have changed the risk and benefit considerations	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Nitric Oxide analyzer not functioning properly	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
No Accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No IRB	[ "Regulatory" ]	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
No Patients enrolled, business objectives have changed"	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
No Patients enrolled; sponsor not providing devices anymore	[ "Logistics_Resources", "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
No Resources - No Personnel	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
No accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No accrual - closed by PRMC	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No accrual due to rarity of disease.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No additional funding is available to continue this pilot study at this time.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
No adequate recruitment	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
No agreement between investigator and sponsor	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
No clinical investigator present	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
No clinical significant	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No continued funding.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
No diagnosis of visceral lesion was placed on 18 included patients. The study is thus stopped prematurely for ethical reasons.	[ "Ethical_Reason" ]	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false
No difference found between two groups in a preliminary analysis	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No difference in 28 day survival among treatment groups (futility). Data analyses showed earlier, but not higher, mortality in the hypertonic saline arms."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No difference in protein excretion at 6&12 months. No safety issues.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No documentation with MHRA to support clinical trial of a medicinal product.	[ "Business_Administrative", "Regulatory" ]	false	true	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false
No efficacy (interim.analysis)	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No eligible candidates in 2 years of recruiting	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No eligible patient.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No eligible patients were enrolled	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No eligible patients were found, the study stopped without including any patients"	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No eligible patients were identified so the study was terminated.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No enrolement	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No enrollment because of war in the study country.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No enrollment in past year, lack of interest"	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
No enrollment occurred. Subjects will be enrolled under a new protocol.	[ "Insufficient_Enrollment", "Study_Design" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
No epidemic of Men C in 2019	[ "Insufficient_Data" ]	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false
No financing possible	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
No focus on this topic	[ "No_Context" ]	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false
No funding	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
No funding and data was not appropriate to consider continuing.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
No funding available.	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false

Medical Monitor action due to lack of compliance with audit.

[ "Study_Design" ]

false

true

false

Medication expired

[ "Logistics_Resources" ]

false

true

false

Medtronic acquisition of Restore Medical, business decision"

[ "Business_Administrative" ]

false

true

false

Melagatran/ximelagatran was withdrawn from the market and clinical development in February 2006 in the interest of patient safety.

[ "Safety_Sideeffects" ]

false

true

false

Melagatran/ximelagatran was withdrawn from the market and clinical development in February Ê 2006 in the interest of patient safety.

[ "Safety_Sideeffects", "Regulatory" ]

false

true

false

Merged with the study NCT00307268

[ "Another_Study" ]

true

false

Met criteria for study futility at interim analysis

[ "Negative" ]

false

true

false

Missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg

[ "Negative" ]

false

true

false

Missing evidence of the effectiveness of the study medication

[ "Negative" ]

false

true

false

Modifications will be necessary before full IRB approval will be secured.

[ "Regulatory" ]

false

true

false

Modified dose schedule presented no advantage over previously studied schedule

[ "Negative" ]

false

true

false

Molecule Development was Terminated

[ "Business_Administrative" ]

false

true

false

More cases of Febrile Neutropenia were observed in experimental group compared to standard treatment.

[ "Safety_Sideeffects" ]

false

true

false

More progressive stroke in one arm

[ "Endpoint_Met" ]

false

true

false

More than 2 of 6 patients treated experienced dose limiting toxicities.

[ "Safety_Sideeffects" ]

false

true

false

Most patients were unable to perform the test being used to measure lung function, thus it became clear the study would not yield clinically meaningful data"

[ "Logistics_Resources" ]

false

true

false

Most pts requested to be treated with versed. It was difficult to randomize pts.

[ "Insufficient_Enrollment" ]

false

true

false

Moved study to USA

[ "Study_Staff_Moved" ]

false

true

false

Multiparas study terminated due to poor recruitment. Randomization revealed only after decision recorded on clinicaltrials.gov

[ "Insufficient_Enrollment" ]

false

true

false

Music therapist left position.

[ "Study_Staff_Moved" ]

false

true

false

Mutual decision by site and sponsor because of difficulty recruiting Patients.

[ "Insufficient_Enrollment" ]

false

true

false

Myriad has discontinued the development of Flurizan.

[ "Business_Administrative" ]

false

true

false

NCI not moving forward with study execution.

[ "Business_Administrative" ]

false

true

false

NIH grant ended.

[ "Business_Administrative" ]

false

true

false

NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.

[ "Negative" ]

false

true

false

NO available budget and difficulty in recruiting

[ "Business_Administrative" ]

false

true

false

NOT A CLINICAL TRIAL

[ "Invalid_Reason" ]

false

true

false

NYU 03-67 reached accrual prior to this study opening.

[ "Another_Study" ]

true

false

Need amendments in application process and require IBD number from FDA

[ "Business_Administrative" ]

false

true

false

Need for re-formulation

[ "Study_Design" ]

false

true

false

Need funding and scientific collaborator

[ "Business_Administrative" ]

false

true

false

Need to review design

[ "Study_Design" ]

false

true

false

Needed PET facility closed

[ "Logistics_Resources" ]

false

true

false

Negative data from another trial led to termination of this trial by sponsor.

[ "Another_Study" ]

true

false

Negative efficacy results of the MAESTRO-01 study

[ "Another_Study" ]

true

false

Negative efficacy results of the MAESTRO-01 trial

[ "Another_Study" ]

true

false

Negative feasibility assessment of recruiting the planned number of subjects within the study timelines

[ "Insufficient_Enrollment" ]

false

true

false

Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part Ê I of the study.

[ "Negative" ]

false

true

false

Negative sorafenib results from ESCAPE trial and safety concerns of regimen

[ "Another_Study" ]

true

false

Negativity of the first results of in vivo binding of 18F-PBR06

[ "Negative" ]

false

true

false

Negotiations in progress regarding payment for drug.

[ "Business_Administrative" ]

false

true

false

Nephrotoxicity

[ "Safety_Sideeffects" ]

false

true

false

Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.

[ "Business_Administrative" ]

false

true

false

Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.

[ "Business_Administrative" ]

false

true

false

Never received final IRB approval for amendments, so never opened officially"

[ "Regulatory" ]

false

true

false

New clinical finding with Celebrex and cardiac concerns.

[ "Another_Study" ]

true

false

New compounds available in the indication (nivolumab/pembrolizumab), toxicity of ipilimumab

[ "Safety_Sideeffects", "Another_Study" ]

true

false

true

false

New data makes this trial unethical

[ "Ethical_Reason" ]

false

true

false

New departmental administration, loss of key study faculty

[ "Study_Staff_Moved" ]

false

true

false

New enrollment has been suspended, currently following previously enrolled participants"

[ "Insufficient_Enrollment" ]

false

true

false

New enrollment is temporarily suspended due to COVID19 restrictions

[ "Covid19" ]

false

true

false

New evidence and trouble recruiting

[ "Another_Study" ]

true

false

New funding sources being sought

[ "Business_Administrative" ]

false

true

false

New information on IMP affected the cost/benefit ratio

[ "Business_Administrative" ]

false

true

false

New information suggested a more effective treatment protocol.

[ "Another_Study" ]

true

false

New medications with improved response released, nonaccrual

[ "Insufficient_Enrollment", "Another_Study" ]

true

false

true

false

New research priorities

[ "Business_Administrative" ]

false

true

false

New studies are being offered

[ "Another_Study" ]

true

false

New study planned.

[ "Business_Administrative", "Another_Study" ]

true

false

New study with lenalidomide pending

[ "Another_Study" ]

true

false

New study written

[ "Another_Study" ]

true

false

Newer technologies available; poor accrual to study.

[ "Study_Design" ]

false

true

false

Newly identified safety concerns have changed the risk and benefit considerations

[ "Safety_Sideeffects" ]

false

true

false

Nitric Oxide analyzer not functioning properly

[ "Logistics_Resources" ]

false

true

false

No Accrual

[ "Insufficient_Enrollment" ]

false

true

false

No IRB

[ "Regulatory" ]

false

true

false

No Patients enrolled, business objectives have changed"

[ "Business_Administrative" ]

false

true

false

No Patients enrolled; sponsor not providing devices anymore

[ "Logistics_Resources", "Insufficient_Enrollment" ]

false

true

false

true

false

No Resources - No Personnel

[ "Logistics_Resources" ]

false

true

false

No accrual

[ "Insufficient_Enrollment" ]

false

true

false

No accrual - closed by PRMC

[ "Insufficient_Enrollment" ]

false

true

false

No accrual due to rarity of disease.

[ "Insufficient_Enrollment" ]

false

true

false

No additional funding is available to continue this pilot study at this time.

[ "Business_Administrative" ]

false

true

false

No adequate recruitment

[ "Study_Design" ]

false

true

false

No agreement between investigator and sponsor

[ "Business_Administrative" ]

false

true

false

No clinical investigator present

[ "Logistics_Resources" ]

false

true

false

No clinical significant

[ "Negative" ]

false

true

false

No continued funding.

[ "Business_Administrative" ]

false

true

false

No diagnosis of visceral lesion was placed on 18 included patients. The study is thus stopped prematurely for ethical reasons.

[ "Ethical_Reason" ]

false

true

false

No difference found between two groups in a preliminary analysis

[ "Negative" ]

false

true

false

No difference in 28 day survival among treatment groups (futility). Data analyses showed earlier, but not higher, mortality in the hypertonic saline arms."

[ "Negative" ]

false

true

false

No difference in protein excretion at 6&12 months. No safety issues.

[ "Negative" ]

false

true

false

No documentation with MHRA to support clinical trial of a medicinal product.

[ "Business_Administrative", "Regulatory" ]

false

true

false

true

false

No efficacy (interim.analysis)

[ "Negative" ]

false

true

false

No eligible candidates in 2 years of recruiting

[ "Insufficient_Enrollment" ]

false

true

false

No eligible patient.

[ "Insufficient_Enrollment" ]

false

true

false

No eligible patients were enrolled

[ "Insufficient_Enrollment" ]

false

true

false

No eligible patients were found, the study stopped without including any patients"

[ "Insufficient_Enrollment" ]

false

true

false

No eligible patients were identified so the study was terminated.

[ "Insufficient_Enrollment" ]

false

true

false

No enrolement

[ "Insufficient_Enrollment" ]

false

true

false

No enrollment

[ "Insufficient_Enrollment" ]

false

true

false

No enrollment because of war in the study country.

[ "Insufficient_Enrollment" ]

false

true

false

No enrollment in past year, lack of interest"

[ "Insufficient_Enrollment" ]

false

true

false

No enrollment occurred. Subjects will be enrolled under a new protocol.

[ "Insufficient_Enrollment", "Study_Design" ]

false

true

false

true

false

No epidemic of Men C in 2019

[ "Insufficient_Data" ]

false

true

false

No financing possible

[ "Business_Administrative" ]

false

true

false

No focus on this topic

[ "No_Context" ]

false

true

false

No funding

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

No funding and data was not appropriate to consider continuing.

[ "Negative" ]

false

true

false

No funding available.

[ "Business_Administrative" ]

false

true

false